CL2015000696A1 - Tratamiento para artritis reumatoide - Google Patents

Tratamiento para artritis reumatoide

Info

Publication number
CL2015000696A1
CL2015000696A1 CL2015000696A CL2015000696A CL2015000696A1 CL 2015000696 A1 CL2015000696 A1 CL 2015000696A1 CL 2015000696 A CL2015000696 A CL 2015000696A CL 2015000696 A CL2015000696 A CL 2015000696A CL 2015000696 A1 CL2015000696 A1 CL 2015000696A1
Authority
CL
Chile
Prior art keywords
rheumatoid arthritis
arthritis treatment
treatment
understands
treat
Prior art date
Application number
CL2015000696A
Other languages
English (en)
Spanish (es)
Inventor
Stefan Haertle
Stephane Leclair
Amgad Shebl
Stefan Steidl
Original Assignee
Morphosys Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Morphosys Ag filed Critical Morphosys Ag
Publication of CL2015000696A1 publication Critical patent/CL2015000696A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/243—Colony Stimulating Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CL2015000696A 2012-09-20 2015-03-19 Tratamiento para artritis reumatoide CL2015000696A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12185235 2012-09-20
US201261703871P 2012-09-21 2012-09-21

Publications (1)

Publication Number Publication Date
CL2015000696A1 true CL2015000696A1 (es) 2015-10-23

Family

ID=46963526

Family Applications (2)

Application Number Title Priority Date Filing Date
CL2015000696A CL2015000696A1 (es) 2012-09-20 2015-03-19 Tratamiento para artritis reumatoide
CL2018000933A CL2018000933A1 (es) 2012-09-20 2018-04-12 Una composición farmacéutica que comprende un anticuerpo anti-factor estimulante de colonias de granulocitos-macrógagos (anti-gm-csf) y vehículos, excipientes o estabilizadores farmacéuticamente aceptables, útil para tratar artritis reumatoide (divisional de la solicitud 696-2015).

Family Applications After (1)

Application Number Title Priority Date Filing Date
CL2018000933A CL2018000933A1 (es) 2012-09-20 2018-04-12 Una composición farmacéutica que comprende un anticuerpo anti-factor estimulante de colonias de granulocitos-macrógagos (anti-gm-csf) y vehículos, excipientes o estabilizadores farmacéuticamente aceptables, útil para tratar artritis reumatoide (divisional de la solicitud 696-2015).

Country Status (23)

Country Link
US (3) US20150246969A1 (pt)
EP (3) EP3345923A1 (pt)
JP (3) JP2015533806A (pt)
KR (4) KR20150056846A (pt)
CN (2) CN104995210A (pt)
AU (2) AU2013320261A1 (pt)
BR (1) BR112015006189B1 (pt)
CA (1) CA2884124A1 (pt)
CL (2) CL2015000696A1 (pt)
CR (1) CR20150153A (pt)
DO (1) DOP2015000070A (pt)
EA (1) EA031489B1 (pt)
HK (1) HK1208231A1 (pt)
IL (1) IL237554B (pt)
IN (1) IN2015KN00657A (pt)
MA (1) MA37946B1 (pt)
MX (2) MX2015003644A (pt)
MY (1) MY175388A (pt)
PE (1) PE20151079A1 (pt)
PH (1) PH12015500591A1 (pt)
SG (2) SG10201803778PA (pt)
UA (1) UA117228C2 (pt)
WO (1) WO2014044768A1 (pt)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA37946B1 (fr) * 2012-09-20 2018-09-28 Morphosys Ag Utilisation d’un anticorps anti-gm-csf pour le traitement de la polyarthrite rhumatoïde
AR093297A1 (es) 2012-10-31 2015-05-27 Amgen Res (Munich) Gmbh Formulacion liquida que comprende un compuesto neutralizante de gm-csf
WO2014068029A1 (en) * 2012-10-31 2014-05-08 Takeda Gmbh Lyophilized formulation comprising gm-csf neutralizing compound
KR20220045064A (ko) 2013-08-30 2022-04-12 다케다 야쿠힌 고교 가부시키가이샤 류마티스성 관절염의 치료에서 또는 진통제로서 사용하기 위한 gm-csf 중화 항체
US11299528B2 (en) * 2014-03-11 2022-04-12 D&D Pharmatech Inc. Long acting TRAIL receptor agonists for treatment of autoimmune diseases
CA2946230A1 (en) * 2014-05-07 2015-11-12 Takeda Gmbh Liquid formulation comprising gm-csf neutralizing compound
GB201519331D0 (en) * 2015-11-02 2015-12-16 Glaxosmithkline Ip Dev Ltd Treatment paradigm
US11007251B2 (en) 2015-12-17 2021-05-18 The Johns Hopkins University Ameliorating systemic sclerosis with death receptor agonists
JP7281795B2 (ja) 2016-04-07 2023-05-26 ザ・ジョンズ・ホプキンス・ユニバーシティー 膵炎および疼痛をデス受容体アゴニストで処置するための組成物および方法
US10647767B2 (en) 2016-09-19 2020-05-12 I-Mab Biopharma Co., Ltd. Anti-GM-CSF antibodies and uses thereof
EP3623382A1 (en) 2018-09-14 2020-03-18 Universität Zürich Ligands to gm-csf or gm-csf-receptor for use in leukemia in a patient having undergone allo-hct
US11655293B2 (en) * 2018-02-22 2023-05-23 Universitat Zurich Ligands to GM-CSF or GM-CSF-receptor for use in leukemia in a patient having undergone allo-HCT
WO2021204649A1 (en) 2020-04-06 2021-10-14 Glaxosmithkline Intellectual Property Development Limited Gm-csf antagonists for use in the treatment of severe pulmonary covid-19, cytokine release syndrome and/or acute respiratory distress syndrome

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
CN1142940C (zh) 1996-10-04 2004-03-24 安姆根有限公司 含有mpl配体的药物组合物
US7455836B2 (en) 2000-05-08 2008-11-25 The University Of Melbourne Method of treatment and agents useful for same
BRPI0610796B8 (pt) * 2005-05-18 2021-05-25 Morphosys Ag anticorpo humano ou humanizado isolado, ou um fragmento fab ou scfv do mesmo, sequência de ácidos nucleicos, vetor, e, uso de um anticorpo
EP1916997B1 (en) 2005-08-05 2018-04-18 Amgen Inc. Stable aqueous protein pharmaceutical formulations and their preparation
WO2007120656A2 (en) * 2006-04-10 2007-10-25 Abbott Biotechnology Ltd. Uses and compositions for treatment of rheumatoid arthritis
WO2008042261A2 (en) * 2006-09-28 2008-04-10 Elusys Therapeutics, Inc. Anti-anthrax antibody, formulations thereof, and methods of use
WO2008064321A2 (en) * 2006-11-21 2008-05-29 Kalobios Pharmaceuticals, Inc. Methods of treating chronic inflammatory diseases using a gm-csf antagonist
EP2703007A1 (en) * 2007-03-30 2014-03-05 MedImmune, LLC Antibodies with decreased deamidation profiles
US20090204489A1 (en) * 2007-04-02 2009-08-13 Genentech, Inc. Biological markers predictive of rheumatoid arthritis response to b-cell antagonists
WO2008122415A1 (en) 2007-04-05 2008-10-16 Sandoz Ag Stable aqueous g-csf formulations
US20090004189A1 (en) * 2007-06-18 2009-01-01 Genentech, Inc. Biological markers predictive of rheumatoid arthritis response to b-cell antagonists
TW200918553A (en) * 2007-09-18 2009-05-01 Amgen Inc Human GM-CSF antigen binding proteins
MX2010005291A (es) * 2007-11-13 2010-11-12 Evec Inc Anticuerpos monoclonales que se unen a hgm-csf y composiciones medicas que comprenden los mismos.
EP2196476A1 (en) * 2008-12-10 2010-06-16 Novartis Ag Antibody formulation
ES2685895T3 (es) * 2008-12-22 2018-10-15 The University Of Melbourne Tratamiento del dolor
CA2746827C (en) 2008-12-22 2018-01-23 The University Of Melbourne Osteoarthritis treatment
JP2010241718A (ja) 2009-04-03 2010-10-28 Kyowa Hakko Kirin Co Ltd 安定な抗体の水溶液製剤
CN102439039A (zh) * 2009-05-05 2012-05-02 莫佛塞斯公司 多发性硬化的治疗
PL2341061T3 (pl) 2009-12-31 2014-09-30 Arven Ilac Sanayi Ve Ticaret As Nowy sposób wytwarzania G-CSF (czynnika stymulującego tworzenie kolonii granulocytów)
WO2011109365A2 (en) * 2010-03-01 2011-09-09 Progenics Pharmaceuticals, Inc. Concentrated protein formulations and uses thereof
RU2013156435A (ru) 2011-07-06 2015-08-20 МорфоСис АГ Терапевтические комбинации анти-cd20 и анти-gm-csf антител и их применения
MA37946B1 (fr) * 2012-09-20 2018-09-28 Morphosys Ag Utilisation d’un anticorps anti-gm-csf pour le traitement de la polyarthrite rhumatoïde

Also Published As

Publication number Publication date
IL237554B (en) 2019-12-31
EP3916013A1 (en) 2021-12-01
KR20220028177A (ko) 2022-03-08
US20180230208A1 (en) 2018-08-16
JP2015533806A (ja) 2015-11-26
MY175388A (en) 2020-06-23
SG11201501595YA (en) 2015-05-28
SG10201803778PA (en) 2018-06-28
PE20151079A1 (es) 2015-08-07
PH12015500591B1 (en) 2015-05-11
UA117228C2 (uk) 2018-07-10
CN109999195A (zh) 2019-07-12
IN2015KN00657A (pt) 2015-07-17
CR20150153A (es) 2015-09-14
KR20150056846A (ko) 2015-05-27
BR112015006189B1 (pt) 2022-04-05
CL2018000933A1 (es) 2018-07-20
US20210130451A1 (en) 2021-05-06
JP2022169709A (ja) 2022-11-09
AU2016250388A1 (en) 2016-11-17
US10913792B2 (en) 2021-02-09
EA201590359A1 (ru) 2015-08-31
BR112015006189A2 (pt) 2019-11-26
MX2015003644A (es) 2015-09-25
HK1208231A1 (en) 2016-02-26
KR20230041086A (ko) 2023-03-23
MX2021006111A (es) 2021-07-07
CN104995210A (zh) 2015-10-21
KR20240091288A (ko) 2024-06-21
MA37946B1 (fr) 2018-09-28
IL237554A0 (en) 2015-04-30
PH12015500591A1 (en) 2015-05-11
EP2897977A1 (en) 2015-07-29
MA37946A1 (fr) 2018-01-31
EP3345923A1 (en) 2018-07-11
CA2884124A1 (en) 2014-03-27
DOP2015000070A (es) 2015-08-16
US20150246969A1 (en) 2015-09-03
AU2016250388B2 (en) 2018-07-19
WO2014044768A1 (en) 2014-03-27
EA031489B1 (ru) 2019-01-31
JP2018138551A (ja) 2018-09-06
AU2013320261A1 (en) 2015-04-09

Similar Documents

Publication Publication Date Title
CL2015000696A1 (es) Tratamiento para artritis reumatoide
CL2015000094A1 (es) Compuestos derivados de imidazotriazincarbonitrilos, inhibidores de la proteina cinasa; composicion farmaceutica que los comprende; y su uso para tratar el cancer, psoriasis y artritis reumatoide.
CL2016000839A1 (es) Composiciones para modular la expresión de c9orf72.
HK1254337A1 (zh) April的抗體分子及其用途
CL2016000807A1 (es) Amino heteroarilo benzamidas como inhibidores de quinasa.
IL246693B2 (en) Antibody molecules to tim-3 and their uses
CL2015002655A1 (es) Moduladores de p2x7
CL2015002562A1 (es) Anticuerpos e inmunoconjugados anti-b7-h4
MX2016003129A (es) Terapia de combinacion de anticuerpos contra el csf-1r humano y anticuerpos contralel pd-l1 humano.
UY34387A (es) Composiciones para el tratamiento de la artritis reumatoide y métodos para su utilización.
GT201400147A (es) Pirimidinas y triazinas fusionadas sustituidas y su uso
BR112016018891A2 (pt) anticorpos anti-dll3 e conjugados de fármacos para uso em melanoma
CL2015003314A1 (es) Inhibidores de acc y usos de los mismos
CL2015000256A1 (es) Compuestos heteroaromáticos, inhibidores de btk, composicion farmaceutica que los comprende y uso en enfermedades tales como artritis reumatoide, lupus, entre otras.
EA201590993A1 (ru) Гетеродимерные иммуноглобулины
CL2012002737A1 (es) Anticuerpo anti-cd40 humanizado; polinucleótido que lo codifica; composición farmacéutica que comprende dicho anticuerpo; y su uso para bloquear una respuesta inmunitaria mediada por cd40 humana.
CL2013002898A1 (es) Compuestos derivados de benceno sustituido con arilo o heteroarilo; composicion farmaceutica que los comprende y uso en el tratamiento del cancer.
BR112016010271A2 (pt) Anticorpo, composição farmacêutica, método de tratamento, uso de um anticorpo e combinação
CL2014001640A1 (es) Composiciones y metodos para anticuerpos dirigidos factor de p; y usos del anticuerpo.
CL2015003049A1 (es) Variantes de pertuzumab y su evaluación
BR112013029773A2 (pt) canabinoides para uso no tratamento de dor neuropática
CL2015002724A1 (es) Métodos para tratar la enfermedad de crohn utilizando un anticuerpo anti-il23
CL2015000752A1 (es) Nuevos ligandos de rig-i y metodos para producirlos
CL2014003339A1 (es) Anticuerpo humanizado anti-trka con propiedades inhibitorias mejoradas; composición que lo comprende; y uso para tratar el dolor.
CL2015000976A1 (es) Compuestos de 2-fenil-5-heterociclil-tetrahidro-2h-piran-3-amina para uso en el tratamiento de diabetes y sus trastornos asociados.